Fusion Antibodies PLC Director dealing (0041C)
January 16 2018 - 4:06AM
UK Regulatory
TIDMFAB
RNS Number : 0041C
Fusion Antibodies PLC
16 January 2018
16 January 2018
Fusion Antibodies plc
("Fusion" or the "Company")
Director+ dealing
Fusion Antibodies (AIM: FAB), a contract research organization
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications, has been advised that Sonya Ferguson, Senior
Independent Director of the Company, has acquired 15,593 ordinary
shares of 4p each in the Company ("Ordinary Shares") at a price of
160p per share. The Ordinary Shares were acquired through her SIPP.
Following this purchase, Sonya Ferguson now has a total beneficial
interest in 15,593 Ordinary Shares, equivalent to 0.07% of the
issued share capital.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities / person closely associated
--- --------------------------------------------------------------
a) Name Sonya Ferguson
--- ------------------------- -----------------------------------
2 Reason for the notification
--- --------------------------------------------------------------
a) Position/status Senior Independent Director
--- ------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- --------------------------------------------------------------
a) Name Fusion Antibodies plc
--- ------------------------- -----------------------------------
b) LEI 213800KBAYRC9VOQ9V39
--- ------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- --------------------------------------------------------------
a) Description of Ordinary shares of GBP0.04
the financial each in Fusion Antibodies
instrument, type plc
of instrument Identification code (ISIN)
Identification for Fusion Antibodies
code plc ordinary shares: GB00BDQZGK16
--- ------------------------- -----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
160p 15,593
--------- ----------
--- ------------------------- -----------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
--- ------------------------- -----------------------------------
e) Date of the transaction 15 January 2018
--- ------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange,
AIM (XLON)
--- ------------------------- -----------------------------------
The information set out in this announcement is provided in
accordance with the requirements of Article 19(3) of the EU Market
Abuse Regulation No 596/2014.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Via Walbrook PR
Officer
James Fair, Chief Financial
Officer
Allenby Capital Limited Tel: +44 (0)20 3328
5656
Virginia Bull / James Reeve
/ Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780 or
fusion@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Anna Dunphy Mob: +44 (0)7876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSFFFSMFASESF
(END) Dow Jones Newswires
January 16, 2018 05:06 ET (10:06 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024